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Background
Perfusion processes have traditionally been used for the
generation of unstable proteins in cell culture systems.
The use of perfusion for production of stable proteins
has been limited by low product concentration, media
costs, and system complexity. With the advent of new
single-use technology and high producing cell lines, per-
fusion processes are gaining increased attention from
industry. Also, the enhanced productivity of perfusion
bioreactor compared to fedbatch enables use of smaller
single-use systems, both for clinical scale production as
well as potentially for manufacturing scale. These new
perfusion processes cannot only be used as a production
platform but also for process intensification of fed-batch
processes. Perfusion can be used to dramatically
increase the cell density of the N-1 bioreactor to accel-
erate the production process and achieve gains in
efficiency.
The critical components of a perfusion system are the
bioreactor controller, cell culture vessel, and cell reten-
tion device. The cell retention device or system is often
used to define the type of perfusion system with gravity-
based and filtration devices being the most common.
This study will show the application of a small-scale
tangential flow microfiltration device(prototype small
scale Prostak™) in a perfusion test platform. This proto-
type device was derived from EMD Millipore Prostak™-
microfiltration family of products typically used in the
primary clarification of cell culture.
Materials and Methods
The 3 channel ProstakTM MF 0.2 um 640 cm2 membrane
prototype small scale devices were obtained from EMD
Millipore Process Solutions R&D. The devices were
pre-sterilized by autoclave. The source and definition of
the components of the bioreactor and system control set
up are listed (Table 1). The recombinant protein produ-
cing CHOS cell line used in this study was previously
shown to express adequately over time and grow rapidly
using a shake flask semicontinous perfusion model.
Results
Results from two separate ssProstakTM perfusion runs
are shown (Figure 1). In the first graph, we show the
ability to grow our model cells to a density of 70E6
cells/ml in 12 days. These high cell densities would be
enabling in N-1 bioreactor applications to shorten seed
train and overall production times. Additionally, the
FogaleTM biomass sensor is confirmed as an accurate
method to track cell viability on-line. In the second
graph, a longer perfusion run is achieved by utilizing
manual daily cell bleed. In the initial perfusion phase
(days 5-24) the cell density is maintained at 30E6 cells/
ml. Healthy cell growth is achieved during this time per-
iod as evidenced by the cell growth curve after each
bleed. In the later perfusion phase, starting at day 25,
cell density was maintained at 40E6 cells/ml with similar
cell growth characteristics and a final viability of >85%.
The utility of using a biomass sensor was also shown in
this run, and we could envision that the sensor data
could be used to automate cell bleeding or the media
perfusion rate. This 30 day perfusion process with the
ssProstakTM is an example of how ProstakTM could be
used in a production perfusion process where the pro-
tein of interest was continuously harvested from the
permeate.
Conclusions
We have demonstrated that a new small scale TFF device
(ssProstakTM) can be used in perfusion applications.
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Currently bioreactor perfusion processes are used for
number reasons including process intensification and
continuous upstream. The data suggest the utility of
ProstakTM in accomplishing these process goals. The
performance metrics measured in this study are similar
to those obtained with other perfusion processes using
hollow fiber TFF cell retention devices, either normal
flow or alternating.
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Table 1. Perfusion Process Details
Materials and Equipment
Cell Line rCHOS
Vessel and Controller 3L Applikon® Glass Bioreactor
Finesse® TruBio™DeltaV
Additional Equipment Single-use recirculation Levitronix™ Pump, Single-use Mobius® 20L bags (Harvest and Medium)
Cell Growth Monitoring - two methods Vi-CELL® (Trypan blue exclusion method)
Biomass by capacitance (iBiomass™ - Fogale™)
Bioreactor Conditions
Vessel Temp (C) 37.0
pH Set Point 7.0 ( ± 0.2)
Dissolved Oxygen (DO) 50%
Aeration Gas/Location Air-Oxygen / Open Pipe
Inoculation Density 3~5E5 vc/mL
Inoculation Agitation 250 rpm (30W/m3)
Working Volume (L) 1.5 L
Daily Cell Bleed Manually (w/ peristaltic pump)
Figure 1 Results from two separate bioreactor perfusion runs using the ssProstak™.
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